dr. chandra belani on selecting the best anti pd-l1 agent in lung cancer
Published 9 years ago • 192 plays • Length 0:58Download video MP4
Download video MP3
Similar videos
-
1:29
dr. chandra p. belani on the importance of immunotherapies in treating lung cancer
-
5:57
multiple pd-1/pd-l1 agents in lung cancer
-
2:07
dr. belani on pd-1 inhibitors for non-small cell lung cancer
-
1:45
dr. chandra belani on atezolizumab in nsclc
-
7:22
pd-1 inhibition in lung cancer
-
2:09
dr. belani on the treatment of lung cancer subgroups
-
4:47
pd-l1 biomarker testing
-
6:10
pd-1 inhibitor use in advanced lung cancer
-
1:02
dr. herbst on pd-1 inhibitors in lung cancer
-
1:37
dr. ready on the benefit of pd-l1 inhibition in sclc
-
2:07
dr. creelan discusses results of anti-pd-l1 antibody in combination with gefitinib in nsclc
-
1:15
dr. rizvi on pd-1 and pd-l1 inhibitors in lung cancer
-
1:11
dr. belani discusses driver mutations in nsclc
-
5:44
reliability of pd-l1 testing in nsclc
-
4:25
pd-1/pd-l1 inhibitors explored across nsclc settings
-
23:02
immunotherapy: moving beyond pd1 and pdl1 inhibitors
-
5:03
pd-l1 less than 49%: available treatments
-
2:50
how different immune checkpoint inhibitors in lung cancer compare?
-
2:56
keynote-010: pembrolizumab, anti-pd-1, for advanced nsclc with pd-l1 expression